<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03087695</url>
  </required_header>
  <id_info>
    <org_study_id>CF17002B</org_study_id>
    <nct_id>NCT03087695</nct_id>
  </id_info>
  <brief_title>Effect of the Plasma EBV DNA Change During Chemoradiotherapy in Nasopharyngeal Carcinoma</brief_title>
  <official_title>Effect of the Plasma EBV DNA Concentration Change During Chemoradiotherapy on Tumor Control and Patient Survival in Advanced Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taichung Veterans General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taichung Veterans General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epstein-Barr virus (EBV) has been proven to process a strong association in patient of
      nasopharyngeal carcinoma (NPC). Monitoring plasma EBV DNA in NPC patients can provide
      reliable informations in early detecting tumor recurrence or risk grouping.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      EBV DNA has strongly association in NPC patient' disease status. It can provide informations
      of disease relapse or risks classification. In this study, we will investigate the impact of
      plasma EBV DNA concentration change during chemoradiotherapy on initial tumor response and
      long-term survival in patients with advanced nasopharyngeal carcinoma
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2017</start_date>
  <completion_date type="Anticipated">January 16, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 16, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>Survival calculation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Survival calculation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasopharynx failure-free survival (NPFFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Survival calculation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neck failure-free survival (NFFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Survival calculation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis failure-free survival (DMFFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Survival calculation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>2 years</time_frame>
    <description>Tumor response evaluated by image</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EBV DNA concentration</measure>
    <time_frame>2 years</time_frame>
    <description>Plasma EBV DNA by real-time polymerase chain reaction (PCR)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Plasma EBV DNA</intervention_name>
    <description>Parameters analyzed will include (1) the change pattern of plasma EBV DNA concentrations, (2) various half-life values (t1/2) of plasma EBV DNA clearance rate calculated over different time periods.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The patients will be collected blood sample once per week during chemoradiotherapy period.
      Plasma will be extracted from these blood sample. Plasma EBV DNA concentrations will be
      measured by a real-time quantitative polymerase chain reaction.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Nasopharyngeal carcinoma patient received definite treatment in Taichung Veteran General
        Hospital
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histological proven NPC.

          2. 2010 American Joint Committee on Cancer (AJCC) stage II-IVB.

          3. Age ≧ 20 years old.

          4. Performance status of Eastern Cooperative Oncology Group (ECOG) ≦ 2.

          5. Adequate liver, renal, and bone marrow functions 5.1 Serum total bilirubin level ≦ 2.5
             mg/dl. 5.2 Serum creatinine ≦ 1.6 mg/dl or calculated creatinine clearance rate (CCr)
             ≧ 60 cc/min.

             5.3 White blood cell count (WBC) ≧ 3,000/micro-ml. 5.4 Platelet count ≧
             100,000/micro-ml.

          6. Pre-treatment plasma EBV DNA &gt; 0 copies/mL

          7. Signed informed consent.

        Exclusion Criteria:

          1. Presence of distant metastasis.

          2. Previous radiotherapy or chemotherapy.

          3. History of a malignancy except those treated with curative intent for skin cancer
             (other than melanoma), in situ cervical cancer, ductal carcinoma in situ (DCIS) of the
             breast.

          4. Severe cardiopulmonary diseases (unstable angina and/or congestive heart failure or
             peripheral vascular disease requiring hospitalization within the last 12 months;
             chronic obstructive pulmonary disease exacerbation or other respiratory illness
             requiring hospitalization) or clinically significant psychiatric disorders.

          5. Female patients who are pregnant or lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jin-Ching Lin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taichung Veterans General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin-Ching Lin, MD, PhD</last_name>
    <phone>+886-4-23592525</phone>
    <phone_ext>5613</phone_ext>
    <email>jclin@vghtc.gov.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yi-Chun Liu, MD</last_name>
    <phone>+886-4-23592525</phone>
    <phone_ext>5621</phone_ext>
    <email>b9202080@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Taichung Veteran General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin-Ching Lin, MD, PhD</last_name>
      <phone>+886-4-23592525</phone>
      <phone_ext>5613</phone_ext>
      <email>jclin@vghtc.gov.tw</email>
    </contact>
    <contact_backup>
      <last_name>Yi-Chun Liu, MD</last_name>
      <phone>+886-4-23592525</phone>
      <phone_ext>5621</phone_ext>
      <email>b9202080@gmil.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2017</study_first_submitted>
  <study_first_submitted_qc>March 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2017</study_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nasopharyngeal carcinoma</keyword>
  <keyword>EBV DNA</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to make individual participant data (IPD) available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

